Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 15Breast Neoplasms 13Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Glioblastoma 10Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Brain Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Leukemia 7Multiple Myeloma 6Hodgkin Disease 6Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, T-Cell, Cutaneous 5Lung Neoplasms 5Gliosarcoma 5Congenital Abnormalities 5Breast Neoplasms, Male 5Recurrence 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Immunoblastic Lymphadenopathy 4

Interventions

Etoposide 4Vincristine 3Rituximab 3Prednisone 3Doxorubicin 3Cyclophosphamide 3prednylidene 2deltacortene 2Cytarabine 2varlilumab 1merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Vorinostat 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Melphalan 1Immunoglobulin G 1Hydrocortisone 1Disulfides 1Carmustine 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Plasmablastic Lymphoma × Vorinostat × Clear all
NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡